Pharma Stocks

Alembic Pharma's revenue from operations increased by 36 per cent YoY to ₹2,603 crore during the said period from ₹1,910 crore a year ago.

Analysts at Systematix Institutional Research and Elara Securities upgraded rating on Dr Reddy's Laboratories stock from 'Hold' to 'Buy' and 'Reduce' to 'Accumulate', respectively.

Solara Active Pharma Sciences reported a consolidated net profit of ₹28.59 crore in Q2FY27 and ₹44.70 crore in H1FY27. It posted a loss of ₹9.29 crore in Q2FY26 and profit of ₹0.42 crore in H1FY26.

IT and FMCG stocks' rally failed to push up a broader market that fell 0.44 per cent on Wednesday, dragged by pharma stocks even as it gained the previous session.

Lerodalcibep licensing deal, growth in the US portfolio and tariff relief offer triggers, while the proposed Organon acquisition could broaden its global reach

Respiratory launches, CDMO expansion and strong US and European businesses are key growth drivers; the stock trades at just under 16 times estimated FY28 earnings

Biocon jumped nearly 3% in Monday's trade after the company's Pertuzumab biosimilar drug received EMA CHMP recommendation for breast cancer care.

The gains in Morepen Labs come on the back of a positive business development announced by the company today involving the first phase of its manufacturing capacity expansion program.

Gland Pharma Share: The market price of Gland Pharma hit a high of ₹2,989.2 in intra-day deals on Tuesday. The stock bounced back 90 per cent from its 52-week low of ₹1,575 touched on March 16, 2026.

In the past month, Laurus Labs outperformed the market by surging 22 per cent, as compared to 2.1 per cent rise in the Nifty Midcap 50 index.

Brokerages see an 11 per cent topline growth in Q1 FY27. HDFC Securities said that the US generic business will be muted due to the absence of gRevlimid, while the India business may grow 13 per cent.

Laurus Labs on Friday reported a 124.7% YoY surge in Q1 consolidated net profit at ₹361.99 crore, backed by 28.8% growth in total income. The stock has nearly doubled in the last one year.

Brokerages largely remain bearish on Dr Reddy's Labs shares following the Q1 earnings show.

Imported generics to remain tariff-free for two years; industry doubts US can build a cost-competitive manufacturing ecosystem within the transition period

As the largest pure-play API/CDMO, Divi's should continue benefiting from custom-synthesis order-book conversion and the structural China+1/BIOSECURE-linked tailwind, analysts believe.

The company said certain batches of semaglutide were found to be out of specification due to issues associated with the API used in the product

Glenmark Pharma stock advanced over 2% in Monday's intra-day trade, after the company's US arm announced the launch of Olanzapine single-dose vial.

Aurobindo Pharma stock hit a 52-week high at ₹1,585, and quoted close to its record high of ₹1,592 hit in September 2024. HDFC Securities maintains 'Add' rating on the stock.

Dr Reddys Laboratories stock hit a fresh 52-week high of ₹1,410 in Monday's intra-day trade, backed by strong surge in trading volume.

Analysts said that a combination of defensive buying, strong earnings visibility, export tailwinds, and sector rotation is driving the rally in pharma stocks.